Garcia, Ana M. published the artcileModulation of cAMP-Specific PDE without Emetogenic Activity: New Sulfide-Like PDE7 Inhibitors, Application In Synthesis of 350-30-1, the publication is Journal of Medicinal Chemistry (2014), 57(20), 8590-8607, database is CAplus and MEDLINE.
A forward chem. genetic approach was followed to discover new targets and lead compounds for Parkinson’s disease (PD) treatment. By anal. of the cell protection produced by some small mols., a di-Ph sulfide compound was revealed to be a new phosphodiesterase 7 (PDE7) inhibitor and identified as a new hit. This result allows us to confirm the utility of PDE7 inhibitors as a potential pharmacol. treatment of PD. On the basis of these data, a diverse family of di-Ph sulfides has been developed and pharmacol. evaluated in the present work. Moreover, to gain insight into the safety of PDE7 inhibitors for human chronic treatment, the authors evaluated the new compounds in a surrogate emesis model, showing nonemetic effects.
Journal of Medicinal Chemistry published new progress about 350-30-1. 350-30-1 belongs to chlorides-buliding-blocks, auxiliary class Fluoride,Chloride,Nitro Compound,Benzene, name is 3-Chloro-4-fluoronitrobenzene, and the molecular formula is C6H3ClFNO2, Application In Synthesis of 350-30-1.
Referemce:
https://en.wikipedia.org/wiki/Chloride,
Chlorides – an overview | ScienceDirect Topics